Complement activation products in tears of dry eye and meibomian gland dysfunction
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-023-46634-7
Abstract: Sixty-seven patients (38 woman; median age, 69 years) were enrolled to assess complement activation products (CAPs) in tear fluid with/without dry eye (DE) and with/without meibomian gland dysfunction (MGD). Patients were divided into four groups based… read more here.
Keywords: meibomian gland; group; mgd; complement activation ... See more keywords
Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2017.1392238
Abstract: ABSTRACT Introduction: Cell-bound complement activation products (CB-CAPs) were first reported in 2004, since which time multiple laboratories have demonstrated their value as biomarkers for diagnosis, monitoring, and stratification of patients with systemic lupus erythematosus. Areas… read more here.
Keywords: medicine; bound complement; biomarkers diagnosis; activation products ... See more keywords